The German Bionorica SE has scheduled a commercial launch of an enterprise near Voronezh for this autumn, but instead of an industrial launch, the project is frozen for a year. The reasons for the suspension of the project are not reported. According to AbiregPR agency, the plant is now manufacturing products in a test mode. The publication said that the company confirmed this information.
Bionorica SE announced plans to build the first plant in Russia for the production of herbal medicines in the Voronezh region in 2013. It was decided that the enterprise will be located in the Maslovsky Industrial Park.
The design capacity of the pharmaceutical plant was supposed to be 120 million blisters per year, with an increase to 200 million blisters by 2020. It was planned to launch the enterprise in 2018. The volume of investments amounted to about 2.5 billion rubles. The project would have created 116 jobs, and by 2020, their number would be 189.
The commemorative capsule was laid in the foundation of the future production in the summer of 2017 by the former governor of the Voronezh Region Alexey Gordeev and the Chairman of Bionorica’s Executive Board, Professor Michael Popp.
During the implementation of the German company’s project, a problem emerged with obtaining long-term certification for the medicines to be produced at the plant that is under construction near Voronezh.
OOO “Bionorika Pharmaceuticals” was registered in Novousmansky district in November 2014 with an authorized capital of 925 million rubles. According to Kartoteka.ru, the owner of the company is Bionorica SE, a European Joint Stock Company. The General director of the Voronezh enterprise is Sergey Strelikov. The balance of the organization is 3.2 billion rubles. With zero revenue, the net loss of the pharmaceutical plant in 2020 amounted to 93.5 million rubles.
